Evogene Partners with QUT to Tackle Lung Cancer Resistance with AI
Event summary
- Evogene is collaborating with Queensland University of Technology (QUT) to develop AI-driven therapeutics for chemotherapy-resistant non-small cell lung cancer (NSCLC).
- The collaboration leverages Evogene’s ChemPass AI™ platform and Dr. Mark Adams’ research on a novel cellular detoxification pathway driving Cisplatin resistance.
- Up to 70% of NSCLC patients treated with Cisplatin experience resistance, highlighting the need for alternative therapies.
- The partnership will focus on identifying druggable mechanisms and generating small-molecule inhibitors to restore treatment sensitivity.
The big picture
Chemotherapy resistance remains a major obstacle in cancer treatment, driving a significant need for innovative therapeutic approaches. Evogene’s collaboration with QUT represents a strategic move to leverage AI-driven drug design to address this challenge, potentially expanding its technology beyond agricultural applications and into a high-value oncology market. The partnership’s focus on a specific, previously unrecognized detoxification pathway suggests a targeted approach that could offer a differentiated therapeutic option.
What we're watching
- Clinical Validation
- The success of this collaboration hinges on the ability to translate the identified cellular pathway into a clinically effective therapeutic target, which will require rigorous preclinical and clinical validation.
- AI Integration
- The iterative refinement of ChemPass AI™ with biological insights from Dr. Adams’ lab will be critical; the platform's ability to incorporate complex biological data will determine the quality of drug candidates generated.
- Competitive Landscape
- Given the significant unmet need in overcoming chemotherapy resistance, Evogene will face competition from other companies pursuing novel therapeutic strategies in NSCLC and other cancers.
Related topics